Meanwhile, the 25-milligram dose of Novo Nordisk's oral semaglutide helped patients lose up to 16.6% of their weight on ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that ...

Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger ...

While both drugs share the same active ingredient, their positioning, pricing, and regulatory pathways diverge sharply, ...

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

Negotiations that could have led to coverage for weight-loss drug Wegovy under Canadian public health plans are not moving ...

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.

Novo Nordisk says it is taking a flexible portfolio approach and plans to price the injectable semaglutide close to Wegovy’s ...